Bosutinib Approved by FDA for Pediatric Patients With Chronic Myelogenous Leukemia
September 27th 2023Bosutinib (Bosulif) is indicated to treat pediatric patients with Philadelphia chromosome–positive chronic-phase chronic myelogenous leukemia that is newly diagnosed, resistant, or intolerant to previous therapy.
Read More
FDA Grants Accelerated Approval to Elranatamab-bcmm for Relapsed or Refractory Multiple Myeloma
August 14th 2023Elranatamab-bcmm (Elrexfio; Pfizer) is a BCMA-CD3-targeted bispecific antibody approved for adults with relapsed or refractory multiple myeloma who were previously administered at least 4 lines of therapy that included a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Read More
FDA Approves Dostarlimab Combination for Primary Advanced or Recurrent Endometrial Cancer
August 1st 2023Dostarlimab-gxly (Jemperli) approved in combination with carboplatin and paclitaxel for the treatment of adults with primary advanced or recurrent endometrial cancer that is mismatch repair deficient.
Read More
Immunoprophylaxis Guidance for RSV Not Aligned With Current Hospitalization Patterns, Study Finds
July 12th 2023Investigators urge policymakers to establish flexible models that maximize coverage when respiratory syncytial virus activity is high and minimize unnecessary doses when viral activity is low.
Read More